Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development and External Validation of a Multiparametric Magnetic Resonance Imaging and International Society of Urological Pathology Based Add-On Prediction Tool to Identify Prostate Cancer Candidates for Pelvic Lymph Node Dissection.
Draulans C, Everaerts W, Isebaert S, Van Bruwaene S, Gevaert T, Oyen R, Joniau S, Lerut E, De Wever L, Laenen A, Weynand B, Defraene G, Vanhoutte E, De Meerleer G, Haustermans K. Draulans C, et al. Among authors: van bruwaene s. J Urol. 2020 Apr;203(4):713-718. doi: 10.1097/JU.0000000000000652. Epub 2019 Nov 13. J Urol. 2020. PMID: 31718396
Current role of surgery for high risk prostate cancer.
Joniau S, Van der Eeckt K, Briganti A, Gontero P, Van Bruwaene S, Jeffrey Karnes R, Spahn M, Van Poppel H; European Multicenter Prostate Cancer Clinical and Translational research Group (EMPaCT). Joniau S, et al. Among authors: van bruwaene s, van der eeckt k, van poppel h. Arch Esp Urol. 2013 Apr;66(3):259-73, 259-74. Arch Esp Urol. 2013. PMID: 23648745 Review. English, Spanish.
Evaluating the Impact of Prostate Only Versus Pelvic Radiotherapy for Pathological Node-positive Prostate Cancer: First Results from the Multicenter Phase 3 PROPER Trial.
Fonteyne V, Van Praet C, Ost P, Van Bruwaene S, Liefhooghe N, Berghen C, De Meerleer G, Vanneste B, Verbaeys C, Verbeke S, Lumen N. Fonteyne V, et al. Among authors: van bruwaene s. Eur Urol Focus. 2023 Mar;9(2):317-324. doi: 10.1016/j.euf.2022.09.005. Epub 2022 Sep 23. Eur Urol Focus. 2023. PMID: 36154809 Free article. Clinical Trial.
Development of a Prospective Data Registry System for Non-muscle-Invasive Bladder Cancer Patients Incorporated in the Electronic Patient File System.
Akand M, Muilwijk T, Cornelissen J, Van Bruwaene S, Vander Eeckt K, Baekelandt F, Mattelaer P, Van Reusel R, Van Cleynenbreugel B, Joniau S, Van Der Aa F. Akand M, et al. Among authors: van bruwaene s, van der aa f, van cleynenbreugel b, van reusel r. Front Oncol. 2019 Dec 11;9:1402. doi: 10.3389/fonc.2019.01402. eCollection 2019. Front Oncol. 2019. PMID: 31921659 Free PMC article.
Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS".
Grimm MO, van der Heijden AG, Colombel M, Muilwijk T, Martínez-Piñeiro L, Babjuk MM, Türkeri LN, Palou J, Patel A, Bjartell AS, Caris C, Schipper RG, Witjes WPJ; EAU Research Foundation NIMBUS Study Group. Grimm MO, et al. Eur Urol. 2020 Nov;78(5):690-698. doi: 10.1016/j.eururo.2020.04.066. Epub 2020 May 20. Eur Urol. 2020. PMID: 32446864 Clinical Trial.
Designing the selenium and bladder cancer trial (SELEBLAT), a phase lll randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium.
Goossens ME, Buntinx F, Joniau S, Ackaert K, Ameye F, Billiet I, Braeckman J, Breugelmans A, Darras J, Dilen K, Goeman L, Kellen E, Tombal B, Van Bruwaene S, Van Cleyenbreuge B, Van der Aa F, Vekemans K, Van Poppel H, Zeegers MP. Goossens ME, et al. Among authors: van cleyenbreuge b, van bruwaene s, van der aa f, van poppel h. BMC Urol. 2012 Mar 21;12:8. doi: 10.1186/1471-2490-12-8. BMC Urol. 2012. PMID: 22436453 Free PMC article. Clinical Trial.
Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC).
Marchioni M, Kriegmair M, Heck M, Amiel T, Porpiglia F, Ceccucci E, Campi R, Minervini A, Mari A, Van Bruwaene S, Linares E, Hevia V, Musquera M, D'Anna M, Derweesh I, Bradshaw A, Autorino R, Guruli G, Veccia A, Roussel E, Albersen M, Pavan N, Claps F, Antonelli A, Palumbo C, Klatte T, Erdem S, Mir MC; EAU-Young Academic Urologist Kidney Cancer Group. Marchioni M, et al. Among authors: van bruwaene s. Eur Urol Oncol. 2021 Apr;4(2):256-263. doi: 10.1016/j.euo.2020.12.010. Epub 2020 Dec 29. Eur Urol Oncol. 2021. PMID: 33384274
Prognosis of node-positive bladder cancer in 2016.
VAN Bruwaene S, Costello AJ, VAN Poppel H. VAN Bruwaene S, et al. Among authors: van poppel h. Minerva Urol Nefrol. 2016 Apr;68(2):125-37. Epub 2016 Mar 3. Minerva Urol Nefrol. 2016. PMID: 26938350 Free article. Review.
Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma.
Roussel E, Campi R, Larcher A, Verbiest A, Antonelli A, Palumbo C, Derweesh I, Ghali F, Bradshaw A, Meagher MF, Heck M, Amiel T, Kriegmair MC, Rubio J, Musquera M, D'Anna M, Autorino R, Guruli G, Veccia A, Linares-Espinos E, Van Bruwaene S, Hevia V, Porpiglia F, Checcucci E, Minervini A, Mari A, Pavan N, Claps F, Marchioni M, Capitanio U, Beuselinck B, Mir MC, Albersen M; Young Academic Urologists Renal Cell Carcinoma Working Group. Roussel E, et al. Among authors: van bruwaene s. Eur Urol Oncol. 2020 Aug;3(4):523-529. doi: 10.1016/j.euo.2020.04.006. Epub 2020 May 12. Eur Urol Oncol. 2020. PMID: 32414697 Free article.
43 results